课题基金 / 基金详情

A Microfluidic Diffusion Immunoassay

A Microfluidic Diffusion Immunoassay
微流控扩散免疫分析
批准号:
6332015
负责人:
PAUL YAGER
金额:
$29.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-05-15 至 2005-04-30

项目摘要

项目成果

PAUL YAGER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
APPLICANT?S DESCRIPTION: One of the most powerful and versatile biomedical diagnostic tools, the immunoassay, is used to monitor the levels of drugs and hormones in body fluids, to diagnose infectious and autoimmune diseases, and to both diagnose and monitor treatment of cancer. The performance of immunoassays is today largely restricted to centralized laboratories because of the need for long assay times, complex and expensive equipment, and highly trained technicians. If a wider range of the 700 million immunoassays performed annually in the US alone could be run more inexpensively, more frequently, and at the point of care, the health of millions of patients could be improved. Recent developments in microfluidics suggest that instruments could soon be developed that would allow immunoassays to be performed as easily as is blood glucose testing today. A microfluidic diffusion immunoassay (DIA) has just been demonstrated that may provide a new set of biochemical processes and a common analytical platform that are well suited to such miniaturized and simplified instrumentation. In this assay, the transport of molecules perpendicular to flow in a microchannel is affected by binding between antigens and antibodies. By imaging the steady-state position of labeled components in a flowing stream, the concentration of very dilute analytes can be measured in a few microliters of sample in seconds. This assay has been demonstrated in the format of a small molecule analyte competition immunoassay using fluorescence imaging detection. The DIA could, then, be used for monitoring drugs, hormones, and other small analytes. Modeling suggests that the current assay can easily detect molecules below the 1-10 nM range in which it has been demonstrated, and could monitor concentrations of analytes as large as proteins, at the cost of increased assay times. Proposed is a 4-year plan to determine, by a series of in vitro tests on increasingly complex samples, the clinical potential of the DIA. To be investigated are 1) the full range of sensitivity and selectivity of the small molecule DIA in the presence of blood and derived biological fluids, and 2) whether the DIA can be extended to detection of large molecule analytes, particularly proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIVAcute: rapid sample-to-result self-testing for HIV RNA
  • 批准号:
    10688240
  • 项目类别:
  • 资助金额:
    $72.07万
  • 财政年份:
    2019
  • 负责人:
    PAUL YAGER
  • 依托单位:
HIVAcute: rapid sample-to-result self-testing for HIV RNA
  • 批准号:
    10214460
  • 项目类别:
  • 资助金额:
    $43.22万
  • 财政年份:
    2019
  • 负责人:
    PAUL YAGER
  • 依托单位:
HIVAcute: rapid sample-to-result self-testing for HIV RNA
  • 批准号:
    9975100
  • 项目类别:
  • 资助金额:
    $43.67万
  • 财政年份:
    2019
  • 负责人:
    PAUL YAGER
  • 依托单位:
HIVAcute: rapid sample-to-result self-testing for HIV RNA
  • 批准号:
    10663626
  • 项目类别:
  • 资助金额:
    $73.84万
  • 财政年份:
    2019
  • 负责人:
    PAUL YAGER
  • 依托单位:
海外基金